Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) This pivotal prospective study ...
Allogeneic hematopoietic-cell transplantation (HCT) in second complete remission achieved 3-year overall survival of 53% and progression-free survival of 46% in adolescents and young adults with acute ...
The findings suggest the presence of CHIP before HCT may have potential to serve as a biomarker for CVD risk after HCT in patients with multiple myeloma. In patients with multiple myeloma, clonal ...
A recent study suggests that patients with myelodysplastic syndrome (MDS) could potentially benefit from allogeneic hematopoietic cell transplantation (HCT) regardless of genetic mutation status.
r-HuEPO 40,000 U one time/week before high-dose melphalan allows a tandem autologous peripheral stem-cell transplantation without red blood cell transfusion in multiple myeloma patients: A pilot study ...
We know from past research that there is a risk of developing cardiovascular disease (CVD) following an autologous hematopoietic cell transplant (HCT). There are several contributing factors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results